Ranbaxy‘s Letrozole Tablets 2.5mg are the generic version of Novartis’ Femara which is approved for the adjuvant treatment of postmenopausal women with hormone receptor-positive early stage breast cancer.
Ranbaxy (UK) Limited, Terapia Ranbaxy and Ranbaxy Pharmacie Generiques are expected to market the drug in the UK, Romania and France respectively.
Ranbaxy, Europe regional director Debashis Dasgupta said the product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the healthcare system in these EU markets.